- Home
- YYGH vs PRLD Comparison
YYGH vs PRLD Comparison
Compare YYGH & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYGH
- PRLD
- Stock Information
- Founded
- YYGH 2010
- PRLD 2016
- Country
- YYGH Singapore
- PRLD United States
- Employees
- YYGH N/A
- PRLD N/A
- Industry
- YYGH
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- YYGH
- PRLD Health Care
- Exchange
- YYGH NYSE
- PRLD Nasdaq
- Market Cap
- YYGH 69.2M
- PRLD 73.7M
- IPO Year
- YYGH 2024
- PRLD 2020
- Fundamental
- Price
- YYGH $1.77
- PRLD $1.05
- Analyst Decision
- YYGH
- PRLD Strong Buy
- Analyst Count
- YYGH 0
- PRLD 2
- Target Price
- YYGH N/A
- PRLD $4.50
- AVG Volume (30 Days)
- YYGH 66.0K
- PRLD 611.2K
- Earning Date
- YYGH 02-21-2025
- PRLD 02-13-2025
- Dividend Yield
- YYGH N/A
- PRLD N/A
- EPS Growth
- YYGH 527.44
- PRLD N/A
- EPS
- YYGH 0.04
- PRLD N/A
- Revenue
- YYGH $37,372,731.00
- PRLD $3,000,000.00
- Revenue This Year
- YYGH N/A
- PRLD N/A
- Revenue Next Year
- YYGH N/A
- PRLD N/A
- P/E Ratio
- YYGH $43.96
- PRLD N/A
- Revenue Growth
- YYGH 55.18
- PRLD N/A
- 52 Week Low
- YYGH $0.72
- PRLD $0.80
- 52 Week High
- YYGH $4.70
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- YYGH N/A
- PRLD 45.27
- Support Level
- YYGH N/A
- PRLD $0.98
- Resistance Level
- YYGH N/A
- PRLD $1.43
- Average True Range (ATR)
- YYGH 0.00
- PRLD 0.12
- MACD
- YYGH 0.00
- PRLD -0.02
- Stochastic Oscillator
- YYGH 0.00
- PRLD 14.14
About YYGH YY GROUP HOLDING LIMITED
YY Group Holding Ltd is a data and technology driven company focused on developing enterprise intelligent labor matching services and smart cleaning services founded in Singapore. It provides enterprise manpower outsourcing and smart cleaning services in Singapore and Malaysia. The group has two operating segment, which is cleaning services segment and manpower outsourcing services, Maximum revenue is generated from cleaning services.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.